COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo

Nordisk said on Wednesday it would drop gender

representation requirements for its U.S. business following

executive orders by President Donald Trump to stop diversity,

equity and inclusion initiatives.

"While Novo Nordisk maintains our global aspiration of a

minimum 45% representation for each gender by the end of 2025,

Novo Nordisk's operations in the U.S. will no longer participate

in this global initiative due to evolving legal requirements,"

the company said in its first-quarter earnings statement.